T cell epitopes from recovered COVID-19 patients identified for vaccine

As the COVID-19 pandemic continues to spread, several vaccines are undergoing clinical trials. However, the current evidence shows that T cell immunity is necessary to provide robust and durable protection against reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This means that the epitopes specific to the virus which are capable of eliciting this type of response across the most significant number of people need to be identified.

A new study by researchers at The Hong Kong University of Science and Technology and published on the preprint server bioRxiv* in August 2020 collates the available database of SARS-CoV-2 T cell epitopes gathered from 8 studies of COVID-19 patients who recovered. This could serve as a launchpad to fill in knowledge gaps regarding the immunological aspects of this disease, and drive towards an effective T cell vaccine.

Study: Epitopes targeted by T cells in convalescent COVID-19 patient. Image Credit: fusebulb / Shutterstock
Study: Epitopes targeted by T cells in convalescent COVID-19 patient. Image Credit: fusebulb
Read More

New American Kidney Fund Education Initiative Provides Expanded Resources for Patients with and at Risk for Polycystic Kidney Disease

ROCKVILLE, MD / ACCESSWIRE / September 4, 2020 / The American Kidney Fund (AKF) today announced a new education initiative focused on autosomal dominant polycystic kidney disease (ADPKD), the most common type of PKD. The initiative is designed to increase awareness of ADPKD, and to provide helpful education resources for those at risk to help facilitate conversations with their health care providers about testing and available treatments.

ADPKD is a genetic disorder characterized by the growth of numerous cysts in the kidneys, causing chronic kidney disease. It is the most commonly inherited form of kidney disease with about 6,000 new cases diagnosed each year in the United States. Symptoms usually develop between the ages of 30 and 40, and about half of patients progress to end-stage renal disease (ESRD, or kidney failure) by age 60. About 2% of new cases of kidney failure are caused by ADPKD.

AKF’s ADPKD awareness

Read More